CM
CABA icon

Churchill Management’s Cabaletta Bio CABA Stock Holding History

Churchill Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,606
Closed -$795K – 152
2024
Q1 		$795K Sell
46,606
-2,750
-6% -$59K 0.01% 145
2023
Q4 		$1.12M Sell
49,356
-7,691
-13% -$129K 0.02% 130
2023
Q3 		$868K Buy
+57,047
New +$780K 0.01% 138

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Churchill Management's CABA Position: Q2 2024 in Review

Churchill Management sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 46,606 shares — an estimated $795K sold.

Churchill Management first reported a position in CABA in Q3 2023 and held it in 3 quarters. The position peaked at $1.12M in Q4 2023. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

  • Churchill Management reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
  • Churchill Management sold 46,606 Cabaletta Bio shares in Q2 2024, an estimated $795K.
  • Churchill Management first reported a position in Cabaletta Bio in Q3 2023 and held it in 3 quarters.
  • Churchill Management's Cabaletta Bio position peaked at $1.12M in Q4 2023.
  • 142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Churchill Management's 13F filing for Q2 2024, filed 22 Jul 2024.